The Differences of N–Acetyl–β–Glucosaminidase and β2 Microglobulin levels in Patients with and without Early Diabetic Nephropathy
DOI:
https://doi.org/10.24293/ijcpml.v28i2.1836Keywords:
Diabetic nephropathy, N-acetyl-β-glucosaminidase, β2 microglobulin, urine albumin creatinine ratioAbstract
Diabetic Nephropathy (DN) is becoming the most serious microvascular complication, which be marked by the presence of persistent albuminuria. N–asetil–β–glucosaminidase is dominant lyzosom enzyme in the renal tubule epitel. β2 microglobulin is low molecular weight protein which produced by major histocompatibility complex class 1 (MHC-1) expressed cell in all nucleated cell. N–asetil–β–glucosaminidase and β2 microglobulin could be new usefull marker for early DN. Analytic observational study with cross sectional approach was conducted in May – July 2019 involving 27 non diabetic patients (K1), 27 diabetic patients without DN (K2) and 27 diabetic patients with early DN (K3) at the Clinical Pathology department of Faculty of Medicine, Diponegoro University and Diabetic Clinic. Data include age, gender, fasting blood glucose, blood preasure and urine albumin creatinine ratio. N–asetil–β–glucosaminidase level between groups were analyzed using Anova, β2 microglobulin level between groups using Kruskal Wallis, p<0.05 were considered significant. There are significant differences in levels of N–asetil–β–glucosaminidase between K1 and K2 (p =0.01), K1 and K3 (p =< 0.01), K2 and K3 (p = 0.03) and β2 microglobulin between K1 and K2 (p = 0.02), K1 and K3 (p =< 0.01), K2 and K3 (p< 0.01). N-acetyl-β-glucosaminidase and β2 microglobulin levels were higher in K2 compared to K1 and increased higher in K3 compared to K1 and K2. N-acetyl-β-glucosaminidase and β2 microglobulin can be used as an alternative marker for early DN.
Downloads
References
American Diabetes Association (ADA). Standard of medical care in diabetes. Diabetes Care. 2017;40(3):s4–s128.
Badan Penelitian dan Pengembangan Kesehatan Kementerian Kesehatan Republik Indonesia. Riskesdas 2018. Jakarta : Kementerian Kesehatan Republik Indonesia. 2018.
Richard J, Mac I, Elif I, Ekinci. Progressive diabetic nephropathy. How useful is microalbuminuria. Kidney Int J.2014;86(1):50–7.
Atul A, Sahil A, Harlokesh N. Pathogenesis of diabetic nephropathy. Int J of pharm sci.2010;2(4):24–9.
Andy AK. Diabetic Nephropathy Complications and Treatment. Int J Nephrol Renovasc Dis.2014;7(2):361-81.
Wei C, Linlin M. Significance of joint detection of urinary proteins with low molecular weight as prognostic indicators for early diagnosis of diabetic nephropathy. Int J Clin Exp Med.2016;9(6):1877-82.
Kern EF, Erhard P, Sun W, Genuth S, Weiss MF. Early urinary markers of diabetic kidney disease: a nested case control study from the Diabetes Control and Complications Trial (DCCT). Am J Kidney Dis.2010;55(5):824-34.
Sheira G, Noreldin N, Tamer A, Saad M. Urinary biomarker N-acetyl-β-D-glucosaminidase can predict severity of renal damage in diabetic nephropathy.J Diab metab disord.2015;14(4):33-6.
Hong CY, Chia KS, Ling SL. Urinary protein excretion in Type 2 diabetes with complications. J Diabetes Complications.2000;14(5):259-65.
Hong N, Lee M, Park S, Lee HY, Jin MS, Hyeon K. Elevated urinary N-acetyl-β-D-glucosaminidase with high glycoalbumin to haemoglobin A1c ratio in diabetes patients with early diabetic kidney disease. Scientific reports.2018;8(3):6710-15.
Inker L, Tighiouart H, Coresh J, Foster M, Anderson A, Beck GJ, Contreras G. GFR Estimation Using β-Trace Protein and β2-Microglobulin in CKD. Am J Kidney Dis. 2016;67(1):40–8.
Aksun SA, Osmen D, Osmen B. β2-Microglobulin and Cystatin C in Type 2 Diabetes: Assessment of Diabetic Nephropathy. Int J Exp Clin Endocr Diab.2004;112(4):195-200.
Kima MK, Yun KJ, Chun HJ, Kwon HS. Clinical utility of serum beta-2-microglobulin as a predictor of diabetic complications in patients with type 2 diabetes without renal impairment. J Elsevier.2014;40(6201):459–65.
Real D, Puchades R, Garcia I. A Study on the Relationship between Serum Beta 2-Microglobulin Levels, Underlying Chronic Kidney Disease, and Peripheral Arterial Disease in High-Vascular-Risk Patients. Int Cardiovasc Res J. 2012;6(4):107-12.
Galle E.A.M, Gillespie K.M. Diabetes and gender. Springer diabet J.2010;44(1):3–15.
Retnakaran R, Cull CA, Thorne KI, Adler AI, Holman RR. Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study. Diabetes Care. 2006;55(6):1832-39.
Dewi J. Cystatin C, HbA1c dan rasio albumin kreatinin. Indonesian Journal of Clinical Pathology and Medical Laboratory.2013;19(3):112-6.
Basturk T, Altuntas Y, Kurklu A, Avdin L, Eren N, Unsai A. Urinary N-acetyl-B glucosaminidase as an earlier marker of diabetic nephropathy and influence of low-dose perindopril/indapamide combination. Ren Fail.2006;28:125-8.
Skalova S. The diagnostic role of urinary N-Acetyl-β-D-Glucosaminidase (NAG) activity in the detection of renal tubular impairment. Acta Med J. 2005; 48(2):75-80.
Zeni L, Norden2 AG, Cancarini G, Robert J. A more tubulocentric view of diabetic kidney disease. J Nephrol.2017;30:701–717
Navarro JF, Mora C, Muros M, Maca M, Garca J. Effects of pentoxifylline administration on urinary N-acetyl- beta-glucosaminidase excretion in type 2 diabetic patients: a short-term, prospective, randomized study. Am J Kidney Dis. 2003;42(2):264–70.
Nauta F, Wendy E., Stephan J.L, Harry V. Glomerular and Tubular Damage Markers Are Elevated in Patients With Diabetes. Diabetes Care.2011;34(4): 975–81
Venugopal S, Iyer UM. Risk factor analysis and prevalence of microalbuminuria among type 2 diabetes mellitus subjects: the need for screening and monitoring microalbuminuria. Asian J Exp Biol SCI.2010;1(3):652-9.
Nikolov G, Boncheva M, Gruev T, Biljali S, Stojceva-Taneva O, Spasovska E. Urinary biomarkers in the early diagnosis of renal damage in diabetes mellitus patients. J Scripta Scientifica Medica.2013;45(3):58–64.
Gluhovschi C, Gluhovschi G, Timar B. Urinary Biomarkers in the Assessment of Early Diabetic Nephropathy. J Diabetes Research. 2016;46(26):1-13
Valdet T, Rame S, Miftari R, Haxhibeqiri V. Association of Beta-2 Microglobulin with Inflammation and Dislipidemia in High-Flux Membrane Hemodialysis Patients. Med Arch.2016;70(5):348-50
Vaia D, Despina K. The relationship between glycemic control, beta2-microglobulin and inflammation in patients on maintenance dialysis treatment. J Diabetes Metab Disord.2015;14(2):34-40
Astor BC, Muth B, Kaufman DB, Pirsch JD, Michael Hofmann R, Djamali A. Serum íŸ2 microglobulin at discharge predicts mortality and graft loss following kidney transplantation. J Int Kidney.2013;84(4):810 7.
Curry C, Thoen J, Shelborne C, Gaudernack G, Messner R. Antibodies to and elevation of beta 2 microglobulin in the serum of ankylosing spondylitis patients. J Arthritis and rheum.2002;25(4):375-80.
Colombo M, Helen C, Farran B, Hees S, Groop L, Colin NA, Turner C, et al. Serum kidney injury molecule 1 and β2-microglobulin perform as well as larger biomarker panels for prediction of rapid decline in renal function in type 2 diabetes. J Diabetologia.2019;62(1):156–68
Downloads
Submitted
Accepted
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
